These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Zang RY, Zhang ZY, Li ZT, Cai SM, Tang MQ, Chen J, Liu Q. Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649 [Abstract] [Full Text] [Related]
3. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR. Cancer; 2006 May 01; 106(9):1933-9. PubMed ID: 16572412 [Abstract] [Full Text] [Related]
4. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, Bristow RE. Cancer; 2007 Feb 15; 109(4):685-91. PubMed ID: 17219441 [Abstract] [Full Text] [Related]
5. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY. Gynecol Oncol; 2006 Dec 15; 103(3):977-84. PubMed ID: 16837030 [Abstract] [Full Text] [Related]
6. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Santillan A, Karam AK, Li AJ, Giuntoli R, Gardner GJ, Cass I, Karlan BY, Bristow RE. Gynecol Oncol; 2007 Mar 15; 104(3):686-90. PubMed ID: 17141302 [Abstract] [Full Text] [Related]
7. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY. Eur J Surg Oncol; 2009 Oct 15; 35(10):1105-8. PubMed ID: 19443175 [Abstract] [Full Text] [Related]
8. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer]. Li YF, Li MD, Liu FY, Liu JH, Li JD. Ai Zheng; 2003 Nov 15; 22(11):1193-6. PubMed ID: 14613651 [Abstract] [Full Text] [Related]
9. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, Gershenson DM. Gynecol Oncol; 2001 May 15; 81(2):237-41. PubMed ID: 11330956 [Abstract] [Full Text] [Related]
10. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR. Gynecol Oncol; 2006 Nov 15; 103(2):559-64. PubMed ID: 16714056 [Abstract] [Full Text] [Related]
11. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Gynecol Oncol; 1999 Mar 15; 72(3):278-87. PubMed ID: 10053096 [Abstract] [Full Text] [Related]
12. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS. Gynecol Oncol; 2006 Dec 15; 103(3):1083-90. PubMed ID: 16890277 [Abstract] [Full Text] [Related]
13. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, Giuntoli RL, Maggioni A. Gynecol Oncol; 2009 Aug 15; 114(2):173-7. PubMed ID: 19482344 [Abstract] [Full Text] [Related]
14. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Leitao MM, Kardos S, Barakat RR, Chi DS. Gynecol Oncol; 2004 Oct 15; 95(1):181-8. PubMed ID: 15385129 [Abstract] [Full Text] [Related]
15. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Fotiou S, Aliki T, Petros Z, Ioanna S, Konstantinos V, Vasiliki M, George C. Gynecol Oncol; 2009 Aug 15; 114(2):178-82. PubMed ID: 19450872 [Abstract] [Full Text] [Related]
16. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Scarabelli C, Gallo A, Carbone A. Gynecol Oncol; 2001 Dec 15; 83(3):504-12. PubMed ID: 11733963 [Abstract] [Full Text] [Related]
17. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Shih KK, Chi DS, Barakat RR, Leitao MM. Gynecol Oncol; 2010 Mar 15; 116(3):364-9. PubMed ID: 19897231 [Abstract] [Full Text] [Related]
18. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Eisenkop SM, Friedman RL, Wang HJ. Gynecol Oncol; 1998 May 15; 69(2):103-8. PubMed ID: 9600815 [Abstract] [Full Text] [Related]
19. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer]. Plaisant N, Quenet F, Fabbro M, Gourgou S, Gutowski M, Saint-Aubert B, Rouanet P. Gynecol Obstet Fertil; 2004 May 15; 32(5):391-7. PubMed ID: 15177208 [Abstract] [Full Text] [Related]